抗細(xì)胞程序性死亡蛋白1配體1抗體(Anti-PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Anti-Programmed Cell Death Protein 1 Ligand 1 Antibody (Anti-PDL1)
CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1
- 編號(hào)UAEA788Mu
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法間接法
- 反應(yīng)時(shí)長2h, 30min
- 檢測(cè)范圍3.12-200ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于1.13ng/mL.
- 樣本類型serum, plasma and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1680 ¥ 2400 ¥ 10800 ¥ 20400 ¥ 168000
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)抗細(xì)胞程序性死亡蛋白1配體1抗體(Anti-PDL1)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的抗細(xì)胞程序性死亡蛋白1配體1抗體(Anti-PDL1)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 80-92 | 88 |
| EDTA plasma(n=5) | 91-104 | 101 |
| heparin plasma(n=5) | 86-101 | 96 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的抗細(xì)胞程序性死亡蛋白1配體1抗體(Anti-PDL1)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中抗細(xì)胞程序性死亡蛋白1配體1抗體(Anti-PDL1)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 90-98% | 80-94% | 78-96% | 82-89% |
| EDTA plasma(n=5) | 98-105% | 99-105% | 81-89% | 82-101% |
| heparin plasma(n=5) | 88-102% | 82-103% | 81-95% | 80-102% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100μL，37°C孵育1小時(shí)；
4. 洗板5次；
5. 加TMB底物90µL，37°C孵育10-20分鐘；
6. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將抗原包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的抗細(xì)胞程序性死亡蛋白1配體1抗體(Anti-PDL1)與連接于固相載體上的抗原結(jié)合，然后加入HRP標(biāo)記的二抗，徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的抗細(xì)胞程序性死亡蛋白1配體1抗體(Anti-PDL1)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA788Mu01 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA788Mu02 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA788Mu01 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體 | WB |
| UPAA788Mu02 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體 | WB |
| USEA788Mu | 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UAEA788Mu | 抗細(xì)胞程序性死亡蛋白1配體1抗體(Anti-PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| ULMA788Mu | 細(xì)胞程序性死亡蛋白1配體1(PDL1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Chinese Journal of Cancer | Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications [NCBI: PMC3937742] |
| Leukemia.? | High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. [Pubmed:24732592] |
| Diabetes?Metab Res Rev. | PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile [Pubmed:24816853] |
| Lancet Haematol | Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study [PubMed: 26686046] |
| Eur J Cancer.? | High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. [Pubmed:27039170] |
| Journal of Cancer Research and Clinical Oncology | Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer [article:10.1007] |
| Journal of Hematology & Oncology | PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma [pubmed:27737703] |
| Lung Cancer. | High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. [pubmed:28212990] |
| Oncotarget | Soluble?programmed?death-ligand?1?(sPDL1) and?neutrophil-to-lymphocyte?ratio?(NLR)?predictssurvival?in?advanced?biliary?tract?cancer?patients?treated?with palliative chemotherapy. [pubmed:27780932] |
| Oncotarget | High?post-treatment?serum?levels?of?soluble?programmed?cell?death?ligand?1?predict?earlyrelapse?and?poor?prognosis?in?extranodal?NK/T?cell?lymphoma patients. [pubmed:27105512] |
| Oncotarget.? | Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma [pubmed:27566569] |
| Cancer Immunol Immunother. | Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. [pubmed:28349165] |
| Leukemia | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients [leu2016385a] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. [pubmed:28207525] |
| Allergology International? | Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients [pubmed:27617656] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy [PMC5319514] |
| American Journal of Respiratory and Critical Care Medicine | Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) [Pdf:10.1164] |
| Clinical Lung Cancer | Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer [Pubmed:29859759] |
| Journal of Rheumatology | Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis [Pubmed:29419471] |
| Translational?Oncology | High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma [Pubmed:29698935] |
| Immunology?Letters | Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals [Pubmed: 30236481] |
| Journal of?Cancer?Research?and?Clinical?Oncology | Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma [Pubmed: 30267213] |
| Annals?of?Surgical?Oncology | Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between?… [Pubmed: 30565045] |
| American Journal of Reproductive Immunology | Identification of programmed cell death 1 and its ligand in the testicular tissue of mice [Pubmed: 30578744] |
| PLoS?One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated?… [Pubmed: 30807610] |
| Endocrine Connections | Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer [Pubmed: 31252406] |
| Scientific Reports | Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer [Pubmed: 31366979] |
| Critical Reviews in Oncology / Hematology | The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer [Pubmed: 31675543] |
| PLoS One | Clinical implications of APOBEC3A and 3B expression in patients with breast cancer [Pubmed: 32176735] |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544] |
| Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma [Pubmed: 32054467] | |
| LIVER INTERNATIONAL | The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer [Pubmed: 32780918] |
| CANCER IMMUNOLOGY IMMUNOTHERAPY | Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients [Pubmed: 32577816] |
| Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure [Pubmed: 32443313] | |
| Cancer Immunol Immunother | The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte [33688997] |
| Acta Biochim Biophys Sin | Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management [34180502] |
| EMBO J | Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology [34825707] |
| Mol Pharm | A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors [34910492] |
| Mol Hum Reprod | Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis [Pubmed:35404426] |
| Journal of Nanobiotechnology | Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape [Pubmed:35705974] |
| Medicina | Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A?… [Pubmed:35208526] |
留言咨詢
